Proteomics Identifies Circulating TIMP-1 as a Prognostic Biomarker for Diffuse Large B-Cell Lymphoma
Proteomics Identifies Circulating TIMP-1 as a Prognostic Biomarker for Diffuse Large B-Cell Lymphoma
复制标题
DOI：
10.1016/j.mcpro.2023.100625
复制
发表时间：
2023
期刊：
影响因子：
--
通讯作者：
Xiaohong Han
中科院分区：
文献类型：
--
作者：
Ning Lou;Guibin Wang;Yanrong Wang;Meng Xu;Yu Zhou;Qiaoyun Tan;Qiaofeng Zhong;Lei Zhang;Xiaomei Zhang;Shuxia Liu;Rongrong Luo;Shasha Wang;Le Tang;Jiarui Yao;Zhishang Zhang;Yuankai Shi;Xiaobo Yu;Xiaohong Han
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease, although disease stratification using in-depth plasma proteomics has not been performed to date. By measuring more than 1000 proteins in the plasma of 147 DLBCL patients using data-independent acquisition mass spectrometry and antibody array, DLBCL patients were classified into four proteomic subtypes (PS-I-IV). Patients with the PS-IV subtype and worst prognosis had increased levels of proteins involved in inflammation, including a high expression of metalloproteinase inhibitor-1 (TIMP-1) that was associated with poor survival across two validation cohorts (n = 180). Notably, the combination of TIMP-1 with the international prognostic index (IPI) identified 64.00% to 88.24% of relapsed and 65.00% to 80.49% of deceased patients in the discovery and two validation cohorts, which represents a 24.00% to 41.67% and 20.00% to 31.70% improvement compared to the IPI score alone, respectively. Taken together, we demonstrate that DLBCL heterogeneity is reflected in the plasma proteome and that TIMP-1, together with the IPI, could improve the prognostic stratification of patients.
